Why the study?
Ventricular tachycardia ablation in patients with ischemic cardiomyopathy has variable outcomes with radiofrequency ablation. Whether new pulsed field ablation technology can achieve similar or superior procedural outcomes over shorter periods with less intravascular fluid infusion had never been tested.
Does endocardial ventricular tachycardia ablation using a focal pulsed field ablation catheter reduce the ablation time needed to eliminate late abnormal ventricular activities compared with standard radiofrequency ablation in patients with ischemic cardiomyopathy?
RCT (n=40)
1:1 block-randomization (block size = 4)
No
Does endocardial ventricular tachycardia ablation using a focal pulsed field ablation catheter reduce the ablation time needed to eliminate late abnormal ventricular activities compared with standard radiofrequency ablation in patients with ischemic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
The ASCEND-VT pilot trial design establishes the first randomized head-to-head protocol evaluating the procedural efficiency and safety of focal pulsed field ablation versus radiofrequency ablation for scar-related ventricular tachycardia in ischemic cardiomyopathy.
Background: Ventricular tachycardia (VT) ablation in patients with ischemic cardiomyopathy (ICM) continues to be a challenging procedure with variable outcomes. Most current ablations are done using radiofrequency ablation (RFA). The new pulsed field ablation (PFA) technology may be able to achieve similar or superior procedural outcomes but potentially over shorter periods of time with less intravascular fluid infusion, but this possibility has never been tested. Objective: This study aimed to compare the procedural efficacy and safety of VT ablation in patients with ICM using focal PFA vs RFA catheters. Methods: This ASCEND-VT pilot study is a single-center trial randomizing patients to RFA vs PFA VT ablation in a 1:1 fashion. The new focal PFA catheter will be used under an investigational device exemption granted by the US Food and Drug Administration. Patients with mechanical valves will be excluded. The primary ablation target will be homogenization of endocardial late abnormal ventricular activity. Patients will be followed for 6 months after the procedure. Results: 40 individuals will be randomized. The primary efficacy metric will be the ablation time needed to eliminate late abnormal ventricular activities in each patient. Additional efficacy and safety endpoints will be interrogated after the procedure and during outpatient follow-up. Conclusion: This is the first pilot randomized controlled trial comparing the safety and efficacy of focal PFA vs RFA VT ablation in ICM. Its results will inform the design of future larger studies that will further establish the clinical utility of PFA in the context of scar-related VT ablation.
No takes yet. Share an insight, caveat, or question.
Sroubek et al. (2026) conducted an RCT in Ischemic cardiomyopathy and sustained monomorphic ventricular tachycardia (n=40). Focal pulsed field ablation (FARAPOINT catheter) vs. Standard radiofrequency ablation (contact force-sensing slow-flow irrigated catheters at 30-50 W for at least 30 seconds) was evaluated on Total ablation time needed to eliminate all targeted late abnormal ventricular activities (LAVAs).
Synapse has enriched 10 related papers. Consider them for comparative context: